VEEV — Veeva Systems Inc.

Is VEEV overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Strong Oversold As of November 17, 2026

Veeva Systems Inc. (VEEV) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $288.48. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Veeva combines a durable subscription revenue model, high margins and deep pharma relationships that support steady cash generation and incremental cross-sell opportunities across Vault and commercial cloud suites. Product breadth and sector-specific positioning create visibility into multi-year deals and recurring revenue, while near-term catalysts include enterprise renewals and new contract wins. Primary risks are a richly priced multiple, execution sensitivity to large-account renewals and potential competitive or regulatory-driven delays in customer spending.

Key factors

  • Recurring, subscription-based revenue model with high gross margins and strong free cash flow generation
  • Deep, entrenched customer relationships across large-cap pharma and biotech that drive high retention and cross-sell potential (Vault, CRM, commercial cloud)
  • Product expansion into regulated content, R&D and commercial workflows increases wallet share and creates multi-year contract visibility
  • Favorable sector dynamics: sustained demand for life-science cloud solutions as pharma invests in digital transformation and specialty/distributor channels expand
  • Prudent balance sheet and operating leverage that supports continued investment in product and go-to-market while maintaining margin profile
  • Near-term catalysts include upcoming quarterly results, new enterprise contract wins, and broader adoption of Vault and commercial offerings

Risks

  • High valuation leaving limited margin for execution shortfalls or macro-driven multiple compression
  • Slowing IT/biopharma spend or delayed large enterprise renewals could pressure growth vs. high expectations
  • Competitive pressures from large cloud providers and niche life-science vendors could affect pricing or deal cadence
  • Customer concentration risk—loss or downsizing of large accounts would materially impact near-term revenue
  • Regulatory or compliance shifts that increase customer churn or extend sales cycles (greater verification or procurement scrutiny)
  • Foreign exchange exposure and macro uncertainty that can depress reported growth and margins

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for VEEV — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.